Exchange: NASDAQ·Updated 07:34 PM EDT
AGIO logo

AGIOAgios Pharmaceuticals Inc

$36.28
$0.23
(0.64%)
Today
Closed $36.28
$0.00
(0.00%)
After Hours
EarningsJul 30
Mkt Cap$2.14B
Vol778,074.00
News
all
press releases
Agios Pharmaceuticals (AGIO) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
Agios Pharmaceuticals (AGIO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks
More News
AGIO Shares Sink Nearly 7% After Scrapping the Tebapivat SCD Program
Agios drops after ending tebapivat development for SCD as phase II data confirmed PK activation but failed to show sufficient clinical differentiation.
Zacks
Why Is AGIO Stock Falling Today?
The biotech firm said it will discontinue development of its therapy for sickle cell disease following the outcome of a Phase 2 trial.
Stocktwits
AGIO's Filing for Mitapivat in SCD Gets FDA's Priority Tag, Stock Up
Agios stock jumps after the FDA accepts and grants priority review to its sNDA for mitapivat in sickle cell disease, with a decision due on Nov. 1, 2026.
Zacks
Strength Seen in Agios Pharmaceuticals (AGIO): Can Its 17.7% Jump Turn into More Strength?
Agios Pharmaceuticals (AGIO) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Zacks
Here's Why Agios Pharmaceuticals Stock Soared Today (Hint: It's FDA-Related)
Key PointsThe company took a major step toward an accelerated approval of mitapivat in sickle cell disease today...
Nasdaq News: Markets
AGIO Stock Hits Over 7-Month Highs – FDA Catalyst, ‘Seasonally Strong’ Q2 Earnings Estimate Drive Optimism
Agios said the U.S. Food and Drug Administration granted Priority Review to its supplemental new drug application for Mitapivat in sickle cell disease.
Stocktwits
DigitalOcean, Agios Pharmaceuticals, Kingsoft Cloud And Other Big Stocks Moving Higher On Tuesday
US stocks were mixed, Nasdaq fell 1%. DigitalOcean shares rose after strong revenue growth and earnings guidance. Other big gainers include CRNX, MAAS, and AGIO.read more...
Benzinga
AGIO Stock Surges 35% in Six Months: What's Driving It?
Agios' shares rose 35% in six months as Aqvesme gains traction, mitapivat expands globally and new ITP rights add to its rare blood disease push.
Zacks
Exelixis (EXEL) Up 6% Since Last Earnings Report: Can It Continue?
Exelixis (EXEL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks
<
1
2
...
>

Advertisement|Remove ads.